An analysis published on October 21, 2026, describes Harmony Biosciences as a strong cash generator, largely because of WAKIX, its narcolepsy treatment. The report compares WAKIX’s revenue stream to a bond with a known maturity date: its market exclusivity is expected to end in 2030.
The main risk is ongoing patent litigation against the one remaining generic challenger. An unfavorable ruling could bring generic competition forward significantly and reduce future cash flows.
The analysis says the current stock price reflects the value of WAKIX’s cash flow and the company’s cash reserves. Its pipeline assets offer additional potential value, but that value remains uncertain.